製药和生物製药合约製造市场－全球产业规模、份额、趋势、机会和预测（按产品类型、服务、地区和竞争细分，2020-2030 年）

2024 年全球製药和生物製药合约製造市场价值为 130.5 亿美元，预计到 2030 年将达到 184.1 亿美元，预测期内的复合年增长率为 6.10%。合约开发和製造组织 (CDMO) 已成为製药和生物技术公司不可或缺的合作伙伴，提供药物配方、活性药物成分 (API) 生产和商业规模製造方面的能力。越来越多的公司将这些业务外包，以减少资本投资、加快产品上市速度，并在不断变化的监管框架和市场条件下保持灵活性。这种趋势在生物製药领域尤其明显，因为生产生物製剂、生物相似药以及细胞和基因疗法的复杂性需要先进的技术和严格的品质标准。儘管成长前景强劲，但市场参与者必须应对日益复杂的监管以及对合规基础设施的持续投资。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

生物製药製造的复杂性

主要市场趋势

更关注细胞和基因治疗製造

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球製药和生物製药合约製造市场的影响

第五章：全球製药和生物製药合约製造市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品类型（活性药物成分 (API)、成品剂型、先进药物输送产品、非处方 (OTC) 药品、其他）
  • 按服务（製药製造服务、生物製剂製造服务、药物开发服务、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美製药和生物製药合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲製药和生物製药合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太製药和生物製药合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲製药和生物製药合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东及非洲製药及生物製药合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：全球製药和生物製药合约製造市场：SWOT 分析

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章：竞争格局

• Jubilant Pharmova Limited
• JRS PHARMA GmbH & Co.
• Boehringer Ingelheim GmbH
• Lonza Group
• Rentschler Biotechnologie GmbH
• Inno Biologics Sdn Bhd
• INCOG BioPharma Services
• Baxter Biopharma Solutions
• Catalent Pharma Solutions
• Kemwell Biopharma Private Limited

第 17 章：策略建议

第18章调查会社について・免责事项

The Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market was valued at USD 13.05 Billion in 2024 and is projected to reach USD 18.41 Billion by 2030, growing at a CAGR of 6.10% during the forecast period. Contract Development and Manufacturing Organizations (CDMOs) have become indispensable partners for pharmaceutical and biotechnology companies, offering capabilities in drug formulation, active pharmaceutical ingredient (API) production, and commercial-scale manufacturing. Increasingly, companies are outsourcing these operations to reduce capital investments, improve speed to market, and maintain agility in the face of evolving regulatory frameworks and market conditions. This trend is especially pronounced in the biopharmaceutical sector, where the complexity of producing biologics, biosimilars, and cell and gene therapies necessitates advanced technologies and rigorous quality standards. Although growth prospects are robust, market players must contend with rising regulatory complexity and the need for continuous investment in compliance infrastructure.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the global healthcare sector, generating over USD 4 trillion in annual revenue, is a significant growth driver for the pharmaceutical and biopharmaceutical contract manufacturing market. With pharmaceuticals and biotechnology contributing nearly USD 850 billion and medical technology and diagnostics adding over USD 400 billion, the healthcare industry is witnessing a growing need for efficient drug production and scalable manufacturing capabilities. To meet these demands, drug developers are increasingly outsourcing to CDMOs, allowing them to focus on R&D and commercialization while leveraging external partners' infrastructure and regulatory expertise. The high costs and long development timelines associated with new drug development-ranging between USD 314 million and USD 4.46 billion-further incentivize the use of contract manufacturers to manage costs, accelerate production, and ensure compliance with evolving regulatory standards.

Key Market Challenges

Complexity in Biopharmaceutical Manufacturing

Biopharmaceutical manufacturing presents considerable complexity, making it a critical challenge for contract manufacturing organizations. Unlike conventional small-molecule drugs, biopharmaceuticals-such as monoclonal antibodies, vaccines, and cell and gene therapies-are derived from living organisms, making their production highly sensitive to variables like temperature, pH, and raw material quality. This complexity necessitates precise control of upstream and downstream processes, as even minor deviations can compromise product safety and efficacy. Consequently, CDMOs must make substantial investments in advanced infrastructure, process optimization, and quality management systems. These demands often lead to longer development cycles and increased operational costs, requiring CDMOs to maintain high levels of expertise and resource allocation.

Key Market Trends

Increased Focus on Cell and Gene Therapy Manufacturing

A defining trend in the market is the rising focus on cell and gene therapy manufacturing. With 76 such therapies launched globally by the end of 2023-more than double the number from a decade prior-this segment is gaining traction due to its promise of targeted, curative treatments for complex diseases. Unlike traditional drug manufacturing, cell and gene therapies involve highly specialized, patient-specific processes that require stringent quality control, cutting-edge bioprocessing, and regulatory precision. Due to these challenges, pharmaceutical companies are increasingly partnering with CDMOs that possess proven capabilities in handling advanced therapeutic modalities. These partnerships enable faster development timelines, greater scalability, and improved regulatory compliance, reinforcing the role of CDMOs as strategic allies in the evolving therapeutic landscape.

Key Market Players

• Jubilant Pharmova Limited
• JRS PHARMA GmbH & Co.
• Boehringer Ingelheim GmbH
• Lonza Group
• Rentschler Biotechnologie GmbH
• Inno Biologics Sdn Bhd
• INCOG BioPharma Services
• Baxter Biopharma Solutions
• Catalent Pharma Solutions
• Kemwell Biopharma Private Limited

Report Scope

In this report, the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Product Type:

• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulation
• Advanced Drug Delivery Products
• Over the Counter (OTC) Medicines
• Others

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Service:

• Pharmaceutical Manufacturing Services
• Biologics Manufacturing Services
• Drug Development Services
• Others

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market.

Available Customizations

Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market

5. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, Advanced Drug Delivery Products, Over the Counter (OTC) Medicines, Others)
  • 5.2.2. By Service (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Service
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Service
  • 6.3.2. Mexico Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Service
  • 6.3.3. Canada Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Service

7. Europe Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Service
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Service
  • 7.3.2. Germany Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Service
  • 7.3.3. United Kingdom Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Service
  • 7.3.4. Italy Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Service
  • 7.3.5. Spain Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Service

8. Asia Pacific Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Service
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Service
  • 8.3.2. India Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Service
  • 8.3.3. South Korea Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Service
  • 8.3.4. Japan Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Service
  • 8.3.5. Australia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Service

9. South America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Service
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Service
  • 9.3.2. Argentina Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Service
  • 9.3.3. Colombia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Service

10. Middle East and Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Service
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Service
  • 10.3.2. Saudi Arabia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Service
  • 10.3.3. UAE Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Service

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Jubilant Pharmova Limited
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. JRS PHARMA GmbH & Co.
• 16.3. Boehringer Ingelheim GmbH
• 16.4. Lonza Group
• 16.5. Rentschler Biotechnologie GmbH
• 16.6. Inno Biologics Sdn Bhd
• 16.7. INCOG BioPharma Services
• 16.8. Baxter Biopharma Solutions
• 16.9. Catalent Pharma Solutions
• 16.10. Kemwell Biopharma Private Limited

17. Strategic Recommendations

18. About Us & Disclaimer